The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...

In 2024 the SMC accepted several other cancer drugs including dabrafenib, known by the brand name Finlee, for use in combination with trametinib (Spexotras), for treating children aged one and older ...

The Scottish Medicines Consortium has approved two new drugs for use with patients via the NHS. Two new medicines have been ...

TWO new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines ...

Patients with generalized pustular psoriasis experienced flares despite the use of traditional off-label therapies and frequently changed treatment.

Boehringer Ingelheim announced new analyses to be presented at the American Academy of Dermatology (AAD) annual meeting in Orlando that explore the effect that SPEVIGO® (spesolimab-sbzo) may have on ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Generalized pustular psoriasis (GPP) can range in severity and may be life threatening for some people. Treatment typically includes a variety of topical, oral, and injectable medications.

1 Guizhou University of Traditional Chinese Medicine, Guiyang, China 2 Department of Dermatology, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China ...

Vanda projects 2025 revenues between $210 million and $250 million, representing growth of 6% to 26% compared to 2024. This forecast includes Fanapt, HETLIOZ, and PONVORY but excludes potential ...

Generalized Pustular Psoriasis Market Outlook 2025-2035: The 7 major generalized pustular psoriasis market reached a value of USD 19.6 Billion in 2024. Looking forward, IMARC Group expects the 7MM to ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...